Numinus Wellness Inc. (OTCPK: NUMI.F)
Health Care · Pharmaceuticals · CA
$0.04
+8.99% today · +1.9% 1Y
Numinus Wellness Inc. (OTCPK: NUMI.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $12.82M and employs 200 people.
Over the last twelve months the share price has gained 1.9%, trading between 0.01 and 0.06.
Tweenvest scores Numinus Wellness Inc. across four factors: quality 12/100, value 59/100, growth 100/100. Its strongest factor is growth.
NUMI.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.82M
- Revenue (TTM)
- $4.71M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 2.59
- 52-week high
- $0.06
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 320.55M
- Employees
- 200
- Next earnings
- —
About Numinus Wellness Inc.
Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.
- ISIN
- CA67054W1032
- Listed since
- May 20, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.